Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G Novacek

Showing results (31-40 of 40) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 40 results.
Gastroenterology|March 1, 1997
Focally enhanced gastritis: a frequent type of gastritis in patients with Crohn's diseaseG Oberhuber, A Püspök, C Oesterreicher, et al.
Zeitschrift Fur Gastroenterologie|March 17, 2016
[In Process Citation]G Novacek, C Dejaco, H P Gröchenig, et al.
Gut|March 16, 2004
Is inflammatory bowel disease an independent and disease specific risk factor for thromboembolism?W Miehsler, W Reinisch, E Valic, et al.
Verhandlungen Der Deutschen Gesellschaft Fur Pathologie|January 1, 1996
[Crohn disease gastritis: histomorphology and immunohistochemical characterization of inflammatory cell infiltrates]F Wrba, G Oberhuber, A Püspök, et al.
Zeitschrift Fur Gastroenterologie|March 29, 2011
[Infliximab therapy for Crohn's disease - a practical guideline: actualised consensus of the working group for chronic inflammatory bowel diseases of the Austrian Society for Gastroenterology and Hepatology]W Reinisch, C Dejaco, T Feichtenschlager, et al.
Alimentary Pharmacology & Therapeutics|September 18, 2012
Retesting for latent tuberculosis in patients with inflammatory bowel disease treated with TNF-α inhibitorsP Papay, C Primas, A Eser, et al.
Alimentary Pharmacology & Therapeutics|December 8, 2011
The impact of intestinal resection on serum levels of anti-Saccharomyces cerevisiae antibodies (ASCA) in patients with Crohn's diseaseA Eser, P Papay, C Primas, et al.
Journal of Crohn'S & Colitis|December 3, 2010
A decade of infliximab: The Austrian evidence based consensus on the safe use of infliximab in inflammatory bowel diseaseW Miehsler, G Novacek, H Wenzl, et al.
Zeitschrift Fur Gastroenterologie|May 18, 2013
[Colorectal cancer: screening and surveillance in inflammatory bowel diseases - consensus of the working group for inflammatory bowel diseases of the Austrian Society of Gastroenterology and Hepatology]S Angelberger, C Campregher, H Fuchssteiner, et al.
Revista De Gastroenterologia De Mexico|March 15, 2015
[Second European evidence-based consensus on the diagnosis and management of ulcerative colitis Part 2: Current management (Spanish version)]A Dignass, J O Lindsay, A Sturm, et al.
Pageof 4

Showing results (31-40 of 40) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 40 results.
Gastroenterology|March 1, 1997
Focally enhanced gastritis: a frequent type of gastritis in patients with Crohn's diseaseG Oberhuber, A Püspök, C Oesterreicher, et al.
Zeitschrift Fur Gastroenterologie|March 17, 2016
[In Process Citation]G Novacek, C Dejaco, H P Gröchenig, et al.
Gut|March 16, 2004
Is inflammatory bowel disease an independent and disease specific risk factor for thromboembolism?W Miehsler, W Reinisch, E Valic, et al.
Verhandlungen Der Deutschen Gesellschaft Fur Pathologie|January 1, 1996
[Crohn disease gastritis: histomorphology and immunohistochemical characterization of inflammatory cell infiltrates]F Wrba, G Oberhuber, A Püspök, et al.
Zeitschrift Fur Gastroenterologie|March 29, 2011
[Infliximab therapy for Crohn's disease - a practical guideline: actualised consensus of the working group for chronic inflammatory bowel diseases of the Austrian Society for Gastroenterology and Hepatology]W Reinisch, C Dejaco, T Feichtenschlager, et al.
Alimentary Pharmacology & Therapeutics|September 18, 2012
Retesting for latent tuberculosis in patients with inflammatory bowel disease treated with TNF-α inhibitorsP Papay, C Primas, A Eser, et al.
Alimentary Pharmacology & Therapeutics|December 8, 2011
The impact of intestinal resection on serum levels of anti-Saccharomyces cerevisiae antibodies (ASCA) in patients with Crohn's diseaseA Eser, P Papay, C Primas, et al.
Journal of Crohn'S & Colitis|December 3, 2010
A decade of infliximab: The Austrian evidence based consensus on the safe use of infliximab in inflammatory bowel diseaseW Miehsler, G Novacek, H Wenzl, et al.
Zeitschrift Fur Gastroenterologie|May 18, 2013
[Colorectal cancer: screening and surveillance in inflammatory bowel diseases - consensus of the working group for inflammatory bowel diseases of the Austrian Society of Gastroenterology and Hepatology]S Angelberger, C Campregher, H Fuchssteiner, et al.
Revista De Gastroenterologia De Mexico|March 15, 2015
[Second European evidence-based consensus on the diagnosis and management of ulcerative colitis Part 2: Current management (Spanish version)]A Dignass, J O Lindsay, A Sturm, et al.
Pageof 4